211 filings
EFFECT
MRSN
Mersana Therapeutics Inc
10 May 24
Notice of effectiveness
12:15am
424B5
MRSN
Mersana Therapeutics Inc
9 May 24
Prospectus supplement for primary offering
5:06pm
10-Q
2024 Q1
MRSN
Mersana Therapeutics Inc
Quarterly report
9 May 24
9:00am
8-K
MRSN
Mersana Therapeutics Inc
9 May 24
Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
7:10am
ARS
2023 FY
MRSN
Mersana Therapeutics Inc
26 Apr 24
Annual report to shareholders
6:25am
DEFA14A
q0wq0m5gbqdc
26 Apr 24
Additional proxy soliciting materials
6:04am
8-K
8ni b64lz9xobpn6b
28 Feb 24
Entry into a Material Definitive Agreement
4:08pm
424B5
2vd1xtntm h5
28 Feb 24
Prospectus supplement for primary offering
4:07pm
POS AM
alkbbs 2r
28 Feb 24
Prospectus update (post-effective amendment)
4:05pm
POSASR
vif077k
28 Feb 24
Automatic shelf registration (post-effective amendment)
8:43am
8-K
79x crogzxly0af6tx
28 Feb 24
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
7:07am
S-8
msbt 78ib7o
12 Jan 24
Registration of securities for employees
4:42pm
8-K
4s00c955d6lgpz jbd
5 Jan 24
Regulation FD Disclosure
8:06am
8-K
9vy w4psteebnhxy
21 Dec 23
Termination of a Material Definitive Agreement
4:11pm
8-K
wx63 68a5nj
7 Nov 23
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
7:18am
8-K
r9cz8htel9r59
31 Oct 23
Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056
8:12am
8-K
bff4jllx ym
12 Sep 23
Regulation FD Disclosure
8:27am